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Association of Body Mass Index With Clinical Outcomes in Patients
With Atrial Fibrillation: A Report From the FANTASIIA Registry
Vicente Bertomeu-Gonzalez, MD, PhD;* Jose Moreno-Arribas, MD, PhD;* Marıa Asuncion Esteve-Pastor, MD, PhD;
Inmaculada Roldan-Rabadan, MD, PhD; Javier Mu~niz, MD, PhD; Paula Ra~na-Mıguez, PhD; Martın Ruiz-Ortiz, MD, PhD;
Angel Cequier, MD, PhD; Vicente Bertomeu-Martınez, MD, PhD; Lina Badimon, MD, PhD; Manuel Anguita, MD, PhD;
Gregory Y. H. Lip, MD; Francisco Marın, MD, PhD; on behalf of FANTASIIA Study Investigators†
Background-—Obesity and atrial fibrillation (AF) frequently coexist and independently increase mortality. We sought to assess the
association between obesity and adverse events in patients receiving oral anticoagulants for AF.
Methods and Results-—Consecutive AF outpatients receiving anticoagulant agents (both vitamin K antagonists and direct oral
anticoagulants) were recruited into the FANTASIIA (Atrial fibrillation: influence of the level and type of anticoagulation on the incidence
of ischemic and hemorrhagic stroke) registry. This observational, multicenter, and prospective registry of AF patients analyzes the
quality of anticoagulation, incidence of events, and differences between oral anticoagulant therapies. We analyzed baseline patient
characteristics according to bodymass index, normal:<25 kg/m2, overweight: 25–30 kg/m2, and obese: ≥30 kg/m2), assessing all-
cause mortality, stroke, major bleeding and major adverse cardiovascular events (a composite of ischemic stroke, myocardial
infarction, and total mortality) at 3 years’ follow-up. In this secondary prespecified substudy, the association of weight on prognosis
was evaluated. We recruited 1956 patients (56% men, mean age 73.89.4 years): 358 (18.3%) had normal body mass index, 871
(44.5%) were overweight, and 727 (37.2%) were obese. Obese patients were younger (P<0.01) and hadmore comorbidities. Mean time
in the therapeutic range was similar across bodymass index categories (P=0.42). After amedian follow-up of 1070 days, 255 patients
died (13%), 45 had a stroke (2.3%), 146 a major bleeding episode (7.5%) and 168 a major adverse cardiovascular event (8.6%). Event
rates were similar between groups for total mortality (P=0.29), stroke (P=0.90), major bleeding (P=0.31), and major adverse
cardiovascular events (P=0.24). On multivariate Cox analysis, body mass index was not independently associated with all-cause
mortality, cardiovascular mortality, stroke, major bleeding, or major adverse cardiovascular events.
Conclusions-—In this prospective cohort of patients anticoagulated for AF, obesity was highly prevalent and was associated with
more comorbidities, but not with poor prognosis. ( J Am Heart Assoc. 2020;9:e013789. DOI: 10.1161/JAHA.119.013789.)
Key Words: atrial fibrillation • mortality • obesity • prognosis • risk factors
O besity and atrial fibrillation (AF) are increasing inepidemic proportions worldwide, and both increase
the incidence of cardiovascular events.1,2 AF has long been
recognized as a risk factor for stroke, and its association with
all-cause mortality is also widely acknowledged.3 While
obesity significantly increases the risk of many metabolic
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and cardiovascular diseases,1–3 it is also associated with a
lower incidence of events once the cardiovascular disease has
been established, as has been proven with conditions such as
diabetes mellitus, chronic kidney disease, stroke, dementia,
coronary artery disease, and heart failure.4–8 This phe-
nomenon is known as the “obesity paradox.”
Obesity has been related to the incidence and progression
of AF,9,10 but its effect on prognosis in AF patients is
controversial.11 Two subanalyses from randomized clinical
trials have shown lower rates of adverse events in patients
with higher body mass index (BMI), the AFFIRM (Atrial
Fibrillation Follow-Up Investigation of Rhythm Management)12
and ARISTOTLE (Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation) trials,13 but this
observation has not been confirmed in observational reg-
istries with real-world data.14 Some authors have proposed
that obese patients may have a more favorable prognosis
because of better anticoagulation control or to a more
complete pharmacological treatment compared with nonob-
ese patients, but results have not been consistent among
different studies.12,14
We sought to assess the role of obesity and BMI on
prognosis in real-world patients receiving oral anticoagulants
for AF.
Methods
The FANTASIIA (Spanish acronym for “Atrial fibrillation:
influence of the level and type of anticoagulation on the
incidence of ischemic and hemorrhagic stroke”) registry
design is described in detail elsewhere.15 In brief, this is an
observational, prospective, national, and multicenter study of
clinical and demographic characteristics of Spanish patients
with AF. Its main objective is to assess the incidence of
thromboembolic and bleeding events in an unselected
population of patients with AF, assessing the type of oral
anticoagulant (ie, vitamin K antagonists (VKA) or direct oral
anticoagulants) used, and the quality of anticoagulation with
VKA. The data that support the findings of this study are
available from the corresponding author upon reasonable
request.
Study Population
Between June 2013 and March 2014, outpatients with
confirmed diagnosis of paroxysmal, persistent, or permanent
AF were prospectively enrolled. All patients included had been
receiving oral anticoagulation for at least 6 months at the
time of recruitment. By design, each investigator included 16
patients taking VKA and 4 patients who were taking direct
oral anticoagulants. Eighty investigators, working in 50
outpatient clinics, performed the study. Exclusion criteria
were as follows: patients with valvular heart disease
(rheumatic valve disease, moderate–severe valve disease,
and prosthesis or valve repair surgery), age younger than
18 years, or with recent hospital admission. The study aimed
to assess the influence of the anticoagulant treatment in
prognosis; thus, patients admitted or with an admission in the
prior 3 months were excluded. All patients provided signed
informed consent.
The study complied with the ethical principles of the
Declaration of Helsinki and Good Clinical Practice Guidelines.
It was approved by the Spanish Agency of Medicine and
Health Products as a prospective follow-up postauthorization
study (approval number SEC-ACO-2012–01) and by the Ethics
Committee of the Hospital Universitario San Juan de Alicante.
Study Variables and Data Collection
Clinical and demographic data for all AF patients were
collected in a detailed medical history. We defined previous
heart disease as the composite of coronary artery disease,
heart failure, and other structural cardiomyopathies (such as
hypertrophic cardiomyopathy, chronic pericardial disease, or
congenital diseases). Coagulation status was determined by
the international normalized ratio values at 6 months before
study entry and at 1 year of follow-up. The estimated time
spent in the therapeutic range was assessed by the Rosendaal
method. Stroke risk was calculated using the CHADS2 and
CHA2DS2-VASc scores,
16,17 bleeding risk using the HAS-BLED
score,18 and comorbidity according to the Charlson index.
Serum creatinine levels were collected at baseline and the
estimated glomerular filtration rate was calculated using the
Cockcroft-Gault formula: ([140–age] 9[weight in kg]9[0.85 if
female]/[729creatinine]). Obesity was assessed at baseline
by means of BMI and stratified as normal weight (<25 kg/
m2), overweight (25 to <30 kg/m2), and obese (≥30 kg/m2).
At 3 years, we assessed incidence of stroke, major
bleeding, all-cause mortality, cardiovascular mortality, and
major adverse cardiovascular events (MACE, defined as the
Clinical Perspective
What Is New?
• Obesity is not associated with prognosis in patients
anticoagulated for atrial fibrillation.
What Are the Clinical Implications?
• While obesity is one of the main risk factors we target to
prevent and treat cardiovascular disease, in the setting of
atrial fibrillation obese patients show similar incidence of
mortality and nonfatal adverse clinical outcomes.
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Table 1. Baseline Characteristics Stratified by BMI
All Patients
Normal Weight
(BMI<25 kg/m2)
Overweight
(BMI 25–30 kg/m2)
Obese
(BMI≥30 kg/m2) P Value
N 1956 358 871 727
Demographic data
Age (y, meanSD) 73.89.4 75.39.5 74.59.5 72.19.2 <0.01
Women, % 44.0 46.7 40.6 46.6 0.03
Comorbidities and cardiovascular risk factors
Arterial hypertension, % 80.4 69.8 79.7 86.5 <0.01
Dyslipidemia, % 52.2 48.6 51.8 54.5 0.18
Diabetes mellitus, % 29.4 24.3 25.5 36.5 <0.01
Smoking habit, % 5.1 5.6 3.9 6.2 0.10
CODP/OSAS, % 17.5 14.5 13.9 23.4 <0.01
Chronic kidney failure, % 19.3 22.6 19.5 17.3 0.11
Liver dysfunction, % 1.2 1.1 1.2 1.4 0.90
Cancer 8.6 9.8 8.2 8.5 0.65
Aortic or peripheral artery disease 6.0 6.7 6.4 5.2 0.51
History of stroke 17.0 20.7 17.6 14.4 0.03
History of systemic embolism 2.2 1.1 1.5 3.6 <0.01
Thyroid dysfunction 11.1 12.0 11.7 10.0 0.49
Alcohol abuse 3.7 3.9 2.3 5.2 <0.01
Charlson index 1.141.16 1.161.20 1.041.14 1.261.15 <0.01
Previous cardiac disease
AF, % 100 100 100 100
Cardiac disease, % 48.0 44.1 45.6 52.7 <0.01
Heart failure, % 28.9 28.2 25.8 32.9 <0.01
Coronary artery diseases, % 18.2 16.2 19.4 17.7 0.39
Acute coronary syndrome, % 13.8 12.6 14.6 13.5 0.62
Coronary revascularization, % 11.5 10.9 12.2 10.9 0.67
Coronary stent, % 9.4 6.9 10.5 9.4 0.17
Dilated cardiomyopathy or LVEF <45% (%) 11.7 13.1 10.6 12.2 0.37
Hypertrophic cardiomyopathy, % 2.6 2.8 2.9 2.2 0.68
Congenital heart disease, % 0.6 1.1 0.2 0.8 0.13
Aortic valve disease, % 3.2 6.2 2.4 2.8 <0.01
Left ventricular hypertrophy, % 15.6 10.3 15.6 18.3 <0.01
Atrial flutter, % 4.4 5.6 3.8 4.5 0.37
Sinus node dysfunction, % 2.6 3.1 2.8 2.1 0.54
Pacemaker 6.5 7.8 6.9 5.4 0.25
Bleeding episodes in the last 6 mo
Major bleeding episodes, % 4.1 5.6 4.1 3.3 0.20
Bleeding requiring transfusion
(% within bleedings)
32.5 35.0 38.9 20.8 0.33
Bleeding requiring surgery
(% within bleedings)
8.8 10.0 5.6 12.5 0.63
Continued
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composite of ischemic stroke, myocardial infarction, and
cardiovascular and all-cause mortality). Thromboembolic
events were defined as stroke or transient ischemic attack
and peripheral artery embolism. All strokes were evaluated by
computed tomography or magnetic resonance imaging
according to the neurologist’s criteria. Bleeding events were
assessed according to the 2005 International Society of
Thrombosis and Haemostasis criteria.19 All-cause and
Table 1. Continued
All Patients
Normal Weight
(BMI<25 kg/m2)
Overweight
(BMI 25–30 kg/m2)
Obese
(BMI≥30 kg/m2) P Value
Type of AF
Paroxysmal, % 29.1 32.7 31.0 25.2 0.14
Persistent, % 16.8 16.8 15.9 17.7
Longstanding persistent, % 4.7 4.2 4.4 5.2
Permanent, % 49.4 46.4 48.7 51.9
Previous electrical cardioversion, % 18.1 14.3 17.3 20.9 0.02
Previous pharmacological cardioversion, % 21.8 21.8 20.8 22.9 0.57
Previous AF ablation, % 4.3 4.5 4.6 3.9 0.76
Control strategy in the baseline visit 0.79
Rhythm control, % 38.2 39.7 37.6 38.2
Rate control, % 61.8 60.3 62.5 61.8
CHADS2 (meanSD) 2.251.24 2.231.34 2.221.21 2.311.24 0.37
CHA2DS2-VASc (meanSD) 3.711.59 3.731.64 3.671.53 3.741.62 0.79
HAS-BLED (meanSD) 2.011.05 2.031.10 1.981.02 2.021.05 0.72
Physical examination
Systolic blood pressure (mm Hg, meanSD) 132.118.5 127.117.4 132.517.7 134.219.5 <0.01
Diastolic blood pressure (mm Hg, meanSD) 75.911.5 72.211.0 75.811.1 77.9711.7 <0.01
Heart rate (bpm, meanSD) 72.715.1 71.816.0 71.814.2 74.115.5 <0.01
Weight (kg, meanSD) 78.514.4 63.48.8 75.08.4 90.213.1 <0.01
Height (cm, meanSD) 164.58.9 164.79.0 165.48.5 163.39.1 <0.01
BMI (kg/m2, meanSD) 28.94.9 23.02.6 27.41.4 33.83.7 <0.01
Complementary examinations
Rhythm at baseline 0.05
Sinus, % 33.0 35.8 35.3 29.0
AF, % 60.6 57.3 57.9 65.5
Pacemaker, % 5.7 5.9 6.2 4.9
Other, % 0.7 1.1 0.6 0.6
LVEF (%, meanSD) 58.611.4 57.812.3 59.111.2 58.311.1 0.09
Left ventricular hypertrophy, % 40.0 33.0 38.1 45.7 <0.01
Hemoglobin (g/dL, meanSD) 13.71.7 13.41.7 13.71.7 13.71.8 <0.01
Serum creatinine (mg/dL, meanSD) 1.10.5 1.10.8 1.00.4 1.00.4 0.05
Glomerular filtration rate
(mL/min per 1.73 m2, meanSD)
66.222.9 60.920.3 64.520.7 70.825.8 <0.01
Total cholesterol (mg/dL, meanSD) 177.138.6 179.840.8 177.236.5 175.639.9 0.10
Glucose (mg/dL, meanSD) 108.631.6 103.227.8 106.329.5 114.134.8 <0.01
HBA1C (%, meanSD) 6.21.3 5.91.2 6.21.1 6.31.6 <0.01
AF indicates atrial fibrillation; BMI, body mass index; bpm, beats per minute; COPD, chronic obstructive pulmonary disorder; HBA1C, hemoglobin A1c; LVEF, left ventricular ejection
fraction; OSAS, obstructive sleep apnea syndrome.
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cardiovascular mortality were also recorded. Death was
classified as cardiovascular when caused by acute coronary
syndrome, heart failure, lethal arrhythmia or sudden death,
artery aneurysm rupture, or stroke. An external event
assignment committee evaluated all adverse events.
Statistical Analyses
The Kolmogorov-Smirnov method was used to test the
normality of continuous variables, which were reported as
meanSD or median (interquartile range), as appropriate.
Categorical variables were expressed as relative frequencies
(%). We used the ANOVA test to compare continuous
variables across BMI categories and the post hoc Tukey test
to assess intergroup differences. Qualitative variables were
compared using the v2 test. Cox regression analyses were
used to test the associations between BMI and mortality,
bleeding, and cardiovascular events. The independent effect
of clinical variables on adverse clinical outcomes was
calculated using a Cox proportional hazards regression; the
multivariate model included variables yielding a P<0.15 on
univariable analysis. The models included BMI, age, sex,
hypertension, dyslipidemia, diabetes mellitus, coronary artery
disease, heart failure, aortic or peripheral artery disease,
chronic kidney disease, Charlson index, history of stroke, and
CHA2DS2-VASc and HAS-BLED scores. Differences in event-
free survival were examined with the log-rank test, and
Kaplan-Meier curves were drafted accordingly. To test
nonlinear association between the continuous variable BMI
and the events, analyses of restricted cubic splines were
performed by generating restricted cubic splines for 4 knots
and adjusting the Cox multivariate model for each event,
including splines as covariates. P<0.05 were considered
statistically significant. All statistical analyses were per-
formed with Stata version 12 (Stata Corporation, College
Station, TX).
Table 2. Pharmacological Treatment at Baseline Stratified by BMI
Normal Weight
(BMI<25 kg/m2)
Overweight
(BMI 25–30 kg/m2)
Obese
(BMI≥30 kg/m2) P Value
N 358 871 727
Diuretics, % 48.9 54.9 64.5 <0.01
Aldosterone antagonists, % 16.2 11.3 16.1 <0.01
ACE inhibitors, % 26.8 31.7 31.8 0.19
Angiotensin receptor blockers, % 32.4 39.5 46.2 <0.01
Statins, % 46.1 55.6 58.7 <0.01
Antiplatelets, % 9.5 11.6 9.9 0.42
b-Blockers, % 55.9 58.1 65.2 <0.01
Digoxin, % 20.9 16.9 18.3 0.24
Antiarrhythmic drugs, % 25.4 25.7 22.9 0.42
ACE indicates angiotensin-converting enzyme; BMI, body mass index.
Table 3. Events During Follow-Up, Stratified by BMI
Normal Weight (BMI<25 kg/m2)
N=358
Overweight (BMI 25–30 kg/m2)
N=871
Obese (BMI≥30 kg/m2)
N=727
P Valuen
Annual Rate
(%/year) n
Annual Rate
(%/year) n
Annual Rate
(%/year)
All-cause mortality 52 (4.84) 119 (4.55) 84 (3.85) 0.29
Cardiovascular
mortality
16 (1.51) 56 (2.18) 35 (1.63) 0.26
Stroke 9 (0.85) 19 (0.74) 17 (0.79) 0.90
Systemic embolism 9 (0.85) 22 (0.84) 17 (0.79) 0.96
Major bleeding 23 (2.18) 75 (2.91) 48 (2.24) 0.22
MACE 24 (2.27) 84 (3.27) 60 (2.79) 0.24
BMI indicates body mass index; MACE, major adverse cardiovascular event (composite of ischemic stroke, myocardial infarction, and cardiovascular and total mortality).
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Results
The final study sample comprised 1956 patients (56% men,
mean age 73.89.4 years). Table 1 shows the baseline
characteristics of the study population. BMI was in the
normal range in 358 (18.3%) patients, while 871 (44.5%)
patients were overweight and 727 (37.2%) were obese. Obese
patients were significantly younger and showed a higher
prevalence of comorbidities such as hypertension, diabetes
mellitus, previous heart failure, and pulmonary disease
compared with normal weight and overweight patients.
Pharmacological Treatment
There were significant differences in most cardiovascular
medications (Table 2), but not in the quality of anticoagulation
control with VKA according to BMI.Mean time in the therapeutic
range was similar across BMI categories (normal weight: 61.1%
versus overweight: 62.5% versus obese: 63.1%; P=0.42). No
significant differences were found in the percentage of VKA
patients achieving <65% or 70% of their time in the therapeutic
range (Table S1).
Events During Follow-Up
After a median of 1070 (interquartile range 750–1110) days of
follow-up, 255 (13.04%) patients had died, including 107
(5.47%) from cardiovascular causes. Forty-five (2.30%) patients
had suffered a stroke, 48 (2.45%) a systemic embolism, 146
(7.46%) a major bleeding episode, and 168 (8.59%) a MACE.
Annual event rates were similar across BMI groups for total
mortality (normal weight: 4.84% versus overweight: 4.55%
versus obese: 3.85%; P=0.29), cardiovascular mortality (normal
weight: 1.51% versus overweight: 2.18% versus obese: 1.63%;
P=0.26), stroke (normal weight: 0.85% versus overweight:
0.74% versus obese: 0.79% P=0.90), systemic embolism
(normal weight: 0.85% versus overweight: 0.84% versus obese:
0.79%; P=0.96), major bleeding (normal weight: 2.18% versus
overweight: 2.91% versus obese: 2.24%; P=0.31), and MACE
(normal weight: 2.27% versus overweight: 3.27% versus obese:
2.79%; P=0.24) (Table 3 and Figure 1).
On univariable analysis, obesity was not statistically related
to all-cause mortality (odds ratio [OR] 1.24, 95% CI 0.94–1.64;
P=0.14, cardiovascular mortality OR 1.23, 95% CI 0.81–1.86;
P=0.33), stroke (OR 0.97, 95% CI 0.53–1.79; P=0.93), systemic
embolism (OR 1.08, 95% CI 0.59–1.97; P=0.80), major bleeding
(OR 1.23, 95% CI 0.86–1.75; P=0.27), or MACE (OR 1.07, 95%
CI 0.77–1.49; P=0.68) (Table S2).
Subgroup Analyses
The event rates were analyzed in prespecified subgroups. We did
not find significant differences between sexes or age groups.
Event rates for death or MACE are shown in Table S2. Only 7
Figure 1. Kaplan–Meier survival estimates. A, Mortality, (B) stroke, (C) major bleeding, and (D) MACE
(composite of ischemic stroke, myocardial infarction, and cardiovascular and total mortality). MACE
indicates major adverse cardiovascular events.
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patients in our population were underweight (BMI<18.5 kg/m2),
precluding further analyses in this category (Table S3).
Multivariate Analysis
In the multivariate Cox analysis performed to adjust for
confounding variables, BMI was not independently associated
with all-cause mortality, cardiovascular mortality, stroke,
major bleeding, or MACE (Table 4). The restricted cubic
splines analyses showed nonlinear relationship between BMI
and events (Figure 2).
An additional model including only BMI and age was
performed in order to further study the effect of age in the
relationship between BMI and events (Figure 3).
Discussion
In a real-world cohort of patients receiving oral anticoagulant
therapy for AF, half of the patients were overweight and a
third were obese. Despite the higher prevalence of cardio-
vascular risk factors in overweight and obese patients, there
were no significant differences in adverse events between
normal and obese patients. Moreover, higher BMI was not
independently associated with a higher risk of mortality or
adverse outcomes in multivariate analysis.
Whether obesity is a protective factor or has no effect is a
matter of debate. In 2 substudies of the ARISTOTLE trial,
overweight and obesity were associated with lower risk of all-
cause mortality, cardiovascular mortality, and stroke even
after adjusting for biomarkers of cardiac and renal dysfunction
and inflammatory activity.13,20 A large meta-analysis and
systematic review evaluated the relationship between BMI
and clinical outcomes in AF patients, finding that the risk of
stroke, death, and cardiovascular death were lower in
overweight and obese patients compared with patients with
a normal BMI,21 but other studies, such as the EORP-AF
(EURObservational Research Programme-Atrial Fibrillation),22
did not find significant differences.
Studies including clinical trial data show reduced events
among obese patients (the so-called “obesity paradox”), while
most observational registries report similar event rates
between obese and normal weight patients, suggesting that
comorbidities have an important role in determining out-
comes.22 Proietti et al23 performed a systematic review
studying the relationship between overweight or obesity and
cardiovascular prognosis and observed an obesity paradox for
adverse events only in clinical trials cohorts, whereas
observational studies fail to show this relationship, in
accordance with our results in the FANTASIIA registry.
Indeed, in our study, the Charlson index was significantly
higher among obese patients, and in the multivariate
analyses it was an independent predictor of mortality, while
obesity did not show significant association. While clinical
trials are considered to provide the highest grade of
evidence, observational registries are better suited for
studying broader populations without strict inclusion criteria,
obtaining information more representative of real-life daily
clinical practice.
Obesity has been shown to be an independent risk factor
for thromboembolic events in the general population with no
AF,14,24 but the relationship between stroke and BMI in
patients with AF is debated. Indeed, scores to predict stroke
do not include BMI, and the 2 variables (stroke and obesity)
are not associated in observational studies.17,25 Our results
corroborate these observations. Although most studies in
patients with AF show neutral or protective effects for higher
BMI, overweight and obesity were associated with a worse
prognosis in the Danish Diet, Cancer, and Health study of
incident AF, a prospective nationwide study.26 The protection
conferred by obesity seems more evident in patients with
established cardiovascular disease, and the selection of
Table 4. Multivariate Cox regression
HR 95% CI P Value
Total mortality
BMI (reference <30 kg/m2) 0.94 0.71 1.25 0.69
Age, per y 1.09 1.07 1.11 <0.01
Heart failure 1.72 1.26 2.36 <0.01
Charlson index 1.33 1.15 1.54 <0.01
CHA2DS2-VASc 0.81 0.69 0.95 0.01
HAS-BLED 1.34 1.16 1.55 <0.01
Stroke
BMI (reference <30 kg/m2) 1.17 0.62 2.22 0.63
Cerebrovascular disease 2.54 1.10 5.88 0.03
Major bleeding
BMI (reference <30 kg/m2) 0.88 0.61 1.28 0.51
Dyslipidemia 0.57 0.41 0.81 0.01
Chronic kidney failure 1.50 1.01 2.23 0.04
HAS-BLED 1.29 1.08 1.55 <0.01
MACE
BMI (reference <30 kg/m2) 1.00 0.72 1.41 0.98
Age, per y 1.06 1.03 1.09 <0.01
Coronary artery disease 1.99 1.26 3.13 <0.01
Heart failure 2.01 1.27 3.16 <0.01
HAS-BLED 1.21 1.01 1.44 0.04
Model adjustment: The models included BMI, age, sex, hypertension, dyslipidemia,
diabetes mellitus, coronary artery disease, heart failure, aortic or peripheral artery
disease, chronic kidney disease, Charlson index, history of stroke, CHA2DS2-VASc and
HAS-BLED scores. BMI indicates body mass index; HR, hazard ratio; MACE, major
adverse cardiovascular event (composite of ischemic stroke, myocardial infarction, and
cardiovascular and total mortality).
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patients with incident AF could result in a lower-risk
population. In fact, in heart failure—the paradigm of advanced
cardiac disease—the obesity paradox is more pronounced.27
The risk of bleeding has scarcely been studied. Our results
suggest that obesity does not modify bleeding risk in patients
anticoagulated for AF, and other studies have shown only that
underweight could be associated with increased bleeding
risk,25,28 but not overweight or obesity. Again, obesity is not
included in any bleeding risk score: neither HAS-BLED nor
ATRIA, HAEMORR2HAGES, or ORBIT include weight among
the variables that predict bleeding episodes.29
Age is one of the strongest predictors of mortality. In our
study, mean age decreased as BMI increased, and this finding
is consistent with other studies.13,20,30 In the subanalysis
including only age and BMI, BMI still did not show a significant
relationship with events in the follow-up.
The higher risk of developing a cardiovascular disease
caused by obesity is probably not as strong as the effect of
cachexia worsening prognosis in any chronic disease. We
speculate that obesity increases the probability of developing
cardiovascular diseases, but it also helps patients survive
their complications. Underweight patients have an increased
mortality risk21,31 and are more prone to have diseases as a
result of poor nutritional status, whereas obesity confers
metabolic reserves that may help to cope with heart disease.
Our results support this hypothesis. Figure 2 shows that
rather than a decrease of risk for obesity, there is an increase
of risk for BMI values <25.
Finally, obese patients may have better tolerance for
cardiovascular drugs with proven prognostic benefits. In our
study, obese patients received a significantly higher propor-
tion of renin-angiotensin system blockers, diuretics, statins,
and b-blockers. This finding is consistent with previous
reports and could explain, at least in part, the good prognosis
associated with obesity. In agreement with other groups, we
found similar international normalized ratio control among
BMI categories,25 but the effect of overweight and obesity on
prognosis did not change after adjustment for these potential
confounders. A nonlinear relationship between BMI and
events was also tested (Figure 2) and we did not find
significant changes in the event rates through all the
spectrum of BMI of our population, reinforcing the lack of
association between weight and prognosis in this scenario.
Limitations
This study has some limitations. BMI was collected only at
baseline, so we could not assess the associations between
Figure 2. Association between BMI and the estimated 3-year survival probability including BMI as a
continuous variable using restricted cubic splines with 3 degrees of freedom. The dotted lines represent the
95% CI. (A) Mortality, (B) stroke, (C) major bleeding, and (D) MACE (composite of ischemic stroke,
myocardial infarction, and cardiovascular and total mortality). The models were adjusted by age, sex,
hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, heart failure, aortic artery disease,
chronic kidney disease, Charlson index, previous stroke, CHA2DS2-VASc, and HAS-BLED. BMI indicates
body mass index; MACE, major adverse cardiovascular events.
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long-term changes in BMI over time on outcomes. The
measurement of obesity by means of BMI is a limited approach,
because it does not assess the distribution of fat, the amount of
lean body weight, body fat, fat-free mass, or fat composition.32
While most studies assess obesity with BMI, results are similar
in studies evaluating it by waist circumference.13,20 The lack of
more detailed information about the type of bleeding or the
cause of cardiovascular death prevented further analyses. The
Cockcroft-Gault formula tends to overestimate creatinine
clearance in obese patients. Although multivariate adjustment
was performed, the effects of residual confounding cannot be
fully excluded. A propensity-scorematched analysis would have
reinforced the strength of the findings, but the limited sample
size of our study prevented us from performing this analysis. On
the other hand, the observational nature of our study provides
real-world data.
In conclusion, in this prospective cohort of real-world
patients anticoagulated for AF, obesity was highly prevalent
but was not associated with poor prognosis. In contrast to
clinical trial cohorts, the obesity paradox does not appear to
be evident in real-world studies.
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Table S1. Quality of antivitamin k control stratified by BMI. 
Normal weight 
(BMI < 25 
kg/m2) 
Overweight 
(BMI 25-30 
kg/m2) 
Obese (BMI 
≥ 30 kg/m2) p value 
N 266 643 574 
TTR Rosendaal (mean ± SD), % 61.1 ± 19.4 62.5 ± 20.7 63.1 ± 19.2 0.42 
TTR < 65% (%) 55.7 52.4 51.1 0.52 
TTR < 70% (%) 64.1 62 62.2 0.87 
BMI: body mass index; SD: standard deviation; TTR: time in the therapeutic range. 
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Table S2. Univariate Cox regression. 
Total mortality HR 95% CI p value 
BMI (reference <30 kg/m2) 0.81 0.62 1.05 0.10 
Female sex 0.79 0.61 1.02 0.12 
Age, per year 1.09 1.07 1.11 <0.01 
Arterial hypertension 1.80 1.25 2.60 <0.01 
Diabetes mellitus 1.60 1.24 2.07 <0.01 
Dyslipidemia 1.02 0.79 1.30 0.90 
Coronary artery disease 1.80 1.37 2.37 <0.01 
Heart failure 2.37 1.85 3.03 <0.01 
Aortic valve disease 1.49 0.96 2.31 0.07 
Chronic kidney failure 2.77 2.13 3.61 <0.01 
Charlson index 1.48 1.36 1.62 <0.01 
Cerebrovascular disease 1.25 0.92 1.70 0.16 
CHA2DS2-VASc 1.39 1.29 1.50 <0.01 
HAS-BLED 1.69 1.52 1.50 <0.01 
Stroke HR 95% CI p value 
BMI (reference <30 kg/m2) 0.99 0.54 1.80 0.97 
Female sex 0.76 0.42 1.39 0.37 
Age, per year 1.02 0.56 1.89 0.27 
Arterial hypertension 1.42 0.63 3.18 0.40 
Diabetes mellitus 1.03 0.54 1.97 0.93 
Dyslipidemia 1.21 0.67 2.18 0.53 
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Coronary artery disease 1.97 1.03 3.75 0.04 
Heart failure 2.21 1.22 3.99 <0.01 
Aortic valve disease 0.76 0.18 3.12 0.69 
Chronic kidney failure 2.26 1.23 4.17 <0.01 
Charlson index 1.36 1.09 1.70 <0.01 
Cerebrovascular disease 2.57 1.38 4.79 <0.01 
CHA2DS2-VASc 1.33 1.11 1.60 <0.01 
HAS-BLED 1.52 1.17 1.96 <0.01 
Major bleeding HR 95% CI p value 
BMI (reference <30 kg/m2) 0.80 0.57 1.14 0.22 
Female sex 0.96 0.69 1.33 0.81 
Age, per year 1.03 1.01 1.05 <0.01 
Arterial hypertension 1.11 0.73 1.68 0.62 
Diabetes mellitus 1.52 1.08 2.13 0.02 
Dyslipidemia 0.67 0.48 0.93 0.02 
Coronary artery disease 1.33 0.90 1.97 0.15 
Heart failure 1.57 1.12 2.20 <0.01 
Aortic valve disease 1.14 0.60 2.17 0.69 
Chronic kidney failure 1.98 1.42 2.78 <0.01 
Charlson index 1.32 1.17 1.49 <0.01 
Cerebrovascular disease 1.47 1.00 2.17 0.05 
CHA2DS2-VASc 1.24 1.12 1.38 <0.01 
HAS-BLED 1.47 1.27 1.70 <0.01 
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MACE HR 95% CI p value 
BMI (reference <30 kg/m2) 0.91 0.66 1.24 0.54 
Female sex 0.90 0.66 1.22 0.49 
Age, per year 1.06 1.04 1.08 <0.01 
Arterial hypertension 1.52 0.99 2.33 0.06 
Diabetes mellitus 2.06 1.51 2.80 <0.01 
Dyslipidemia 1.49 1.09 2.04 0.01 
Coronary artery disease 2.80 2.05 3.84 <0.01 
Heart failure 2.73 2.01 3.69 <0.01 
Aortic valve disease 2.20 1.38 3.52 <0.01 
Chronic kidney failure 2.46 1.79 3.38 <0.01 
Charlson index 1.52 1.36 1.69 <0.01 
Cerebrovascular disease 1.39 0.96 2.01 0.08 
CHA2DS2-VASc 1.45 1.32 1.59 <0.01 
HAS-BLED 1.60 1.40 1.82 <0.01 
 
BMI: body mass index; CI: confidence interval; HR: hazard ratio.  
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Table S3. Event rates for subgroups, stratified by BMI. 
 
 Normal weight  
(BMI < 25 kg/m2) 
N = 358 
Overweight  
(BMI 25-30 kg/m2) 
N = 871 
Obese  
(BMI ≥ 30 kg/m2) 
N = 727  
 
n 
Annual 
rate 
(%/year) n 
Annual 
rate 
(%/year) n 
Annual 
rate 
(%/year) 
p 
value 
All-cause mortality      
Age        
< 65 
years 
4 (2.83) 5 (1.32) 4 (0.91) 0.23 
65-75 
years 
9 (2.75) 31 (3.47) 25 (8.33) 0.80 
> 75 
years 
39 (6.44) 83 (6.19) 55 (6.03) 0.93 
Sex        
Women 19 (3.79) 44 (2.54) 35 (3.44) 0.68 
Men 33 (5.76) 75 (4.84) 49 (4.21) 0.32 
MACE        
Age        
< 65 
years 
4 (2.83) 6 (1.59) 6 (1.37) 0.53 
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65-75 
years 
5 (1.53) 21 (2.35) 23 (2.77) 0.47 
> 75 
years 
15 (2.48) 57 (4.25) 31 (3.40) 0.12 
Sex        
Women 12 (2.39) 27 (2.54) 31 (3.05) 0.70 
Men 12 (2.09) 57 (3.67) 29 (2.49) 0.07 
BMI: body mass index; MACE: major adverse cardiovascular events (composite of ischemic stroke, myocardial 
infarction and cardiovascular and total mortality). 
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